Genetic Profiling of Liver Cancer in Patients Undergoing Liver Transplantation

Baylor Scott and White Health (BSWH)

Status: Completed

Conditions: Hepatocellular Carcinoma

Treatments: Other: None - Standard of Care

Study type: Observational

Funder types: Other

Identifiers

NCT02412579

014-121

Details and patient eligibility

About

The purpose of this study is to determine whether genetic markers unique to liver cancer are present and to assess usefulness as a diagnostic tool.

Full description

Hepatocellular carcinoma (HCC) is the most common form of liver cancer and a growing trend worldwide. Decision-making regarding treatment for patients is limited by the lack of clinically actionable biomarkers. This is pronounced in the case for determining and monitoring liver transplant recipients. In an effort to improve diagnosis, the use of circulating serum-based microRNA isoforms (isomiRs) can serve as non-invasive, screening biomarkers in HCC patients pre- and post-transplantation of the liver.

Enrollment: 40 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with the diagnosis of HCC who are on the wait list for liver transplantation
• Patients with the diagnosis of HCC who have been admitted to hospital, scheduled to undergo liver transplantation within the following 24 hours.
• Age Range: 18 to 75 years old

Exclusion criteria

• Patients with metastatic HCC and patients with the diagnosis of HCC who are not on the wait list for liver transplantation.
• Patients older than 75 years old and younger than 18 years old.
• Patients who are unable to consent.
• Pregnant patients.

Trial design

40 participants in 2 patient groups

Hepatocellular Carcinoma with Cirrhosis

Description:

Subjects with hepatocellular carcinoma and cirrhosis.

Treatment:

Other: None - Standard of Care

Cirrhosis without Hepatocellular Carcinoma

Description:

Subjects with only cirrhosis.

Treatment:

Other: None - Standard of Care